文献速递临床试验与 GCP

θ爆发式刺激对比高频重复经颅磁刺激治疗抑郁症(THREE-D):随机非劣效性试验

Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial.
PubMed 文献 · Lancet · 2018-04-26

在难治性重性抑郁障碍成人中开展的随机多中心非劣效性试验显示,间歇性θ爆发式刺激(iTBS)在改善HRSD-17评分方面不劣于10 Hz重复经颅磁刺激(rTMS),两组脱落率与安全性相似,iTBS可缩短每次治疗时间。

要点

  • iTBS在改善抑郁症状方面不劣于10 Hz rTMS
  • 两组脱落率和不良事件相似,iTBS组自评疼痛强度略高

核心结论

  • 在难治性抑郁患者中,iTBS在改善抑郁症状方面不劣于10 Hz rTMS。
  • 两种治疗脱落率低,副作用、安全性和耐受性特征相似。

研究设计与样本

  • 随机、多中心、非劣效性临床试验,在加拿大三家大学医院招募18-65岁难治性抑郁患者。
  • 治疗为开放标签,但研究者和结局评估者设盲;每周5天,持续4-6周。

主要发现

  • 最常见治疗相关不良事件为头痛(10 Hz rTMS组131/204[64%],iTBS组136/208[65%])。

临床怎么用

  • iTBS可作为难治性抑郁的rTMS治疗选项,其疗效不劣于10 Hz rTMS且单次治疗时间更短。
  • 使用iTBS可在不损害临床疗效的前提下增加每日治疗患者数量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment-resistant major depressive disorder is common; repetitive transcranial magnetic stimulation (rTMS) by use of high-frequency (10 Hz) left-side dorsolateral prefrontal cortex stimulation is an evidence-based treatment for this disorder. Intermittent theta burst stimulation (iTBS) is a newer form of rTMS that can be delivered in 3 min, versus 37·5 min for a standard 10 Hz treatment session. We aimed to establish the clinical effectiveness, safety, and tolerability of iTBS compared with standard 10 Hz rTMS in adults with treatment-resistant depression. METHODS: In this randomised, multicentre, non-inferiority clinical trial, we recruited patients who were referred to specialty neurostimulation centres based at three Canadian university hospitals (Centre for Addiction and Mental Health and Toronto Western Hospital, Toronto, ON, and University of British Columbia Hospital, Vancouver, BC). Participants were aged 18-65 years, were diagnosed with a current treatment-resistant major depressive episode or could not tolerate at least two antidepressants in the current episode, were receiving stable antidepressant medication doses for at least 4 weeks before baseline, and had an HRSD-17 score of at least 18. Participants were randomly allocated (1:1) to treatment groups (10 Hz rTMS or iTBS) by use of a random permuted block method, with stratification by site and number of adequate trials in which the antidepressants were unsuccessful. Treatment was delivered open-label but investigators and outcome assessors were masked to treatment groups. Participants were treated with 10 Hz rTMS or iTBS to the left dorsolateral prefrontal cortex, administered on 5 days a week for 4-6 weeks. The primary outcome measure was change in 17-item Hamilton Rating Scale for Depression (HRSD-17) score, with a non-inferiority margin of 2·25 points. For the primary outcome measure, we did a per-protocol analysis of all participants who were randomly allocated to groups and who attained the primary completion point of 4 weeks. This trial is registered with ClinicalTrials.gov, number NCT01887782. FINDINGS: Between Sept 3, 2013, and Oct 3, 2016, we randomly allocated 205 participants to receive 10 Hz rTMS and 209 participants to receive iTBS. 192 (94%) participants in the 10 Hz rTMS group and 193 (92%) in the iTBS group were assessed for the primary outcome after 4-6 weeks of treatment. HRSD-17 scores improved from 23·5 (SD 4·4) to 13·4 (7·8) in the 10 Hz rTMS group and from 23·6 (4·3) to 13·4 (7·9) in the iTBS group (adjusted difference 0·103 [corrected], lower 95% CI -1·16; p=0·0011), which indicated non-inferiority of iTBS. Self-rated intensity of pain associated with treatment was greater in the iTBS group than in the 10 Hz rTMS group (mean score on verbal analogue scale 3·8 [SD 2·0] vs 3·4 [2·0] out of 10; p=0·011). Dropout rates did not differ between groups (10 Hz rTMS: 13 [6%] of 205 participants; iTBS: 16 [8%] of 209 participants); p=0·6004). The most common treatment-related adverse event was headache in both groups (10 Hz rTMS: 131 [64%] of 204; iTBS: 136 [65%] of 208). INTERPRETATION: In patients with treatment-resistant depression, iTBS was non-inferior to 10 Hz rTMS for the treatment of depression. Both treatments had low numbers of dropouts and similar side-effects, safety, and tolerability profiles. By use of iTBS, the number of patients treated per day with current rTMS devices can be increased several times without compromising clinical effectiveness. FUNDING: Canadian Institutes of Health Research.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018. PMID: 29726344. doi:10.1016/S0140-6736(18)30295-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。